Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS)

Historical Holders from Q2 2020 to Q4 2025

Type / Class
Equity / Common Stock, $0.0001 par value per share
Symbol
KROS on Nasdaq
Shares outstanding
30,284,111
Price per share
$20.36
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
35,272,183
Holdings value
$558,013,727
% of all portfolios
0%
Share change
-672,146
Value change
-$7,638,921
Average buys %
+0%
Average sells %
-0%
Number of holders
150
Price from insider filings
$17.75
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Madison Avenue Partners, LP 6.4% $32,000,280 2,614,402 Madison Avenue Partners, LP 07 May 2025
VANGUARD GROUP INC 6.3% $31,411,769 2,566,321 The Vanguard Group 31 Mar 2025
TANG CAPITAL MANAGEMENT LLC 7.9% $38,268,569 2,418,984 TANG CAPITAL MANAGEMENT, LLC 15 Oct 2025
ExodusPoint Capital Management, LP 6.3% $28,675,722 1,907,899 ExodusPoint Capital Management, LP 10 Nov 2025
D. E. SHAW & CO, L.P. 5.1% $24,457,052 1,545,948 D. E. Shaw & Co., L.P. 20 Oct 2025
ALKEON CAPITAL MANAGEMENT LLC 2.7% $13,476,240 1,101,000 Alkeon Capital Management LLC 31 Dec 2024
FMR LLC 1.7% $8,622,737 704,472 FMR LLC 31 Jan 2025
JPMORGAN CHASE & CO 0.2% -102% $1,392,949 -$30,273,718 113,803 -96% JPMORGAN CHASE & CO. 30 Apr 2025
As of 30 Sep 2025, Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) has 150 institutional shareholders filing 13F forms. They hold 35,272,183 shares .

Top 25 institutional shareholders own 99% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
ADAR1 Capital Management, LLC 18% 5,389,264 0% 8.5% $85,258,156
VANGUARD GROUP INC 9% 2,718,777 +3.3% 0% $43,011,052
BlackRock, Inc. 9% 2,717,153 -0.57% 0% $42,985,352
Madison Avenue Partners, LP 8.9% 2,708,218 +0.62% 2.6% $42,844,009
Western Standard LLC 7.2% 2,189,882 +43% 19% $34,643,933
TANG CAPITAL MANAGEMENT LLC 4.7% 1,418,984 0% 0.86% $22,448,327
D. E. Shaw & Co., Inc. 4.4% 1,331,425 +2.6% 0.02% $21,063,144
GOLDMAN SACHS GROUP INC 4.4% 1,325,483 +50% 0% $20,969,141
STATE STREET CORP 4.3% 1,302,978 -5.9% 0% $20,613,112
Nantahala Capital Management, LLC 4.1% 1,233,189 -24% 1.2% $19,509,050
ORBIMED ADVISORS LLC 3.4% 1,018,734 0% 0.39% $16,116,372
ALKEON CAPITAL MANAGEMENT LLC 2.8% 850,511 0% 0.06% $13,455,084
Logos Global Management LP 2.8% 850,000 -58% 1.3% $13,447,000
GEODE CAPITAL MANAGEMENT, LLC 2.8% 837,363 +0.97% 0% $13,249,727
JACOBS LEVY EQUITY MANAGEMENT, INC 2% 607,089 +16% 0.04% $9,604,148
Redmile Group, LLC 1.8% 552,506 0% 0.85% $8,740,645
FEDERATED HERMES, INC. 1.7% 514,160 -21% 0.01% $8,134,011
MORGAN STANLEY 1.3% 395,103 -55% 0% $6,250,537
Connor, Clark & Lunn Investment Management Ltd. 1.1% 335,154 +26% 0.02% $5,302,136
PDT Partners, LLC 1.1% 332,815 0% 0.33% $5,265,133
NORTHERN TRUST CORP 1.1% 332,758 +22% 0% $5,264,231
Qube Research & Technologies Ltd 1% 303,122 +684% 0.01% $4,795,390
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.96% 292,006 +3% 0% $4,619,535
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 0.85% 258,754 +301% 0% $4,093,488
Rangeley Capital, LLC 0.85% 258,619 -9.4% 3.9% $4,091,353

Institutional Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 386 $7,859 +$122 $20.36 2
2025 Q3 35,272,183 $558,013,727 -$7,638,921 $15.82 150
2025 Q2 35,929,823 $480,098,478 +$53,894,968 $13.35 136
2025 Q1 32,796,190 $334,209,202 -$101,548,952 $10.19 154
2024 Q4 36,741,898 $581,639,646 -$99,581,030 $15.83 158
2024 Q3 34,948,467 $2,029,993,419 +$197,498,863 $58.07 163
2024 Q2 31,463,055 $1,436,820,755 -$1,911,760 $45.70 149
2024 Q1 31,373,529 $2,076,887,534 +$418,851,985 $66.20 144
2023 Q4 49,766 $1,986,050 -$1,393,270 $39.76 3
2023 Q3 22,805,528 $727,049,650 +$8,072,263 $31.88 103
2023 Q2 22,410,570 $900,473,463 +$13,069,977 $40.18 119
2023 Q1 21,997,538 $936,743,919 +$93,563,471 $42.70 127
2022 Q4 19,737,738 $947,809,522 +$89,058,501 $48.02 119
2022 Q3 17,520,689 $659,108,717 +$33,180,521 $37.62 100
2022 Q2 17,216,554 $475,702,189 +$7,906,812 $27.63 96
2022 Q1 15,582,726 $847,129,266 +$4,508,877 $54.38 96
2021 Q4 15,702,583 $917,924,734 +$68,273,148 $58.51 92
2021 Q3 13,786,856 $544,829,923 -$17,082,591 $39.56 86
2021 Q2 12,875,335 $546,804,079 -$44,327,639 $42.47 77
2021 Q1 14,400,116 $886,300,984 -$122,195,808 $61.55 81
2020 Q4 15,819,144 $1,114,418,058 +$300,498,502 $70.54 78
2020 Q3 11,466,826 $442,276,430 +$34,041,921 $38.57 47
2020 Q2 10,926,163 $409,790,602 +$409,462,563 $37.51 51